SCHEMBL26215401

SCHEMBL26215401

O=[N+]([O-])c1ccc(-c2cc(C(F)(F)F)ccn2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN2A Q99250 1/20 0.50
▸ MAPT P10636 4/20 0.48
▸ KIF11 P52732 2/20 0.47
▸ TLR2 O60603 1/20 0.46
▸ TLR1 Q15399 1/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ RAD51 Q06609 1/20 0.44
▸ PIK3CA P42336 2/20 0.44
▸ PIK3CB P42338 2/20 0.44
▸ PIK3CG P48736 2/20 0.44
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ HSP90AA1 P07900 1/20 0.43
▸ CXCR5 P32302 1/20 0.43
▸ APLNR P35414 1/20 0.43
▸ CCR6 P51684 1/20 0.43
▸ ABCC8 Q09428 1/20 0.43
▸ KCNJ11 Q14654 1/20 0.43
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14082731 0.85 TRPV1 (0.58) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL27764812 0.80 KIF11 (0.52) KIF11NOS3NOS2
SCHEMBL1258187 0.78 PIK3CA (0.50) SCN2AMAPTTLR2TLR1ALDH1A1
SCHEMBL26215416 0.78 MAPT (0.50) SCN2AMAPTKIF11TLR2TLR1
SCHEMBL28726704 0.77 NOS3 (0.48) KIF11ALDH1A1MEN1KMT2ANPC1
SCHEMBL29002760 0.76 MAPT (0.52) MAPTALDH1A1PIK3CAPIK3CBPIK3CG
SCHEMBL27491688 0.76 ASIC3 (0.56) MAPTALDH1A1PIK3CAPIK3CBPIK3CG
SCHEMBL11166231 0.76 ALDH1A1 (0.52) MAPTTLR2TLR1ALDH1A1RAD51
SCHEMBL3157555 0.76 PTGS2 (0.52) KIF11PTGS1
SCHEMBL24168950 0.76 NOS3 (0.56) KIF11PTGS1NOS3NOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583815-B2 Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof BRIDGENE BIOSCIENCES, INC. (US) 2026-03-24 — — US disclosed
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 — — US disclosed
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. 2023-09-14 — — US disclosed
CN-116490201-A Inhibitors of YAP/TAZ-TEAD tumor proteins, their synthesis and use 布里奇恩生物科学公司 2023-07-25 — — CN disclosed
EP-4175658-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF Bridgene Biosciences, Inc. (US) 2023-05-10 — — EP disclosed
WO-2022006548-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF BRIDGENE BIOSCIENCES, INC. (US) 2022-01-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12583815-B2 Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof YAP1, TEAD1, TEAD2 SCN2A 3116/4885MAPT 371/4885KIF11 2467/4885
US-20230286904-A1 INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF TEAD1, TEAD2, TEAD3 SCN2A 4594/4885MAPT 433/4885KIF11 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback